EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants

Yue Hu iD, Haijun Li, Kun Wang, Dandan Wu, Hong Zhang, Yanhua Ding iD, Junyan Wu, Suiwen Ye, Yun Peng, Li Liu iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01450-24 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Yue Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Center, First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Antiviral Agents, Coronavirus 3C Proteases, COVID-19 Drug Treatment, Protease Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019, which leads to pneumonia, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RAY1216 is a 3C-like protease inhibitor that targets SARS-CoV-2. The aim of our study was to assess the pharmacokinetics (PK) and safety of RAY1216 in healthy volunteers. This was a randomized, placebo-controlled, double-blind study consisting of four components: a single ascending dose study, a drug-drug interaction study, a multiple ascending dose study, and a food-effect study. All participants were randomly assigned to receive either a single dose or multiple doses of RAY1216 or placebo. A total of 88 healthy adult participants (male-to-female ratio of 1:1) aged 18–50 years were enrolled. A total of 37 participants (42%) experienced at least one adverse event (AE). All AEs were mild or moderate and were resolved without additional treatment. The most commonly reported adverse drug reactions were hypertriglyceridemia, hyperuricemia, and elevated serum creatinine levels. RAY1216 was well-absorbed after administration with exposure increasing in a dose-dependent manner. Food appeared to increase exposure and delay the absorption of RAY1216. Ritonavir significantly inhibited drug metabolism, and increased drug exposure increased the associated safety risks. RAY1216 was found to be well tolerated and safe in healthy participants. On the basis of preclinical results, PK characteristics, and the safety profile of RAY1216, a dosage of 400 mg three times daily was selected, thereby establishing a foundation for future research and for the clinical application of RAY1216. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT05829551 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCoronavirus 3C ProteasesCOVID-19 Drug TreatmentProtease InhibitorsAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultCOVID-19Double-Blind MethodFood-Drug InteractionsHealthy VolunteersSARS-CoV-2

Stichwörter der Autor:innen

3CL protease inhibitorCOVID-19RAY1216pharmacokineticssafety

Substanzen

Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors

Autor:innen und Institutionen

  • Phase I Clinical Research Center, First Hospital of Jilin University, Changchun, China.
  • Department of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
  • Guangdong Raynovent Biotech Co., Ltd., Guangzhou, China.
  • Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China.
  • Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Pediatrics, First Hospital of Jilin University, Changchun, China.

ORCID-Profile: Yue Hu, Yanhua Ding, Li Liu

Zitieren

APA

Hu, Y., Li, H., Wang, K., Wu, D., Zhang, H., Ding, Y., Wu, J., Ye, S., Peng, Y., & Liu, L. (2025). Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01450-24

Vancouver

Hu Y, Li H, Wang K, Wu D, Zhang H, Ding Y, et al. Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01450-24

BibTeX
@article{Hu2025,
  author = {Hu, Yue and Li, Haijun and Wang, Kun and Wu, Dandan and Zhang, Hong and Ding, Yanhua and Wu, Junyan and Ye, Suiwen and Peng, Yun and Liu, Li},
  title = {Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01450-24}
}
Kostenlos starten →